Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt 2.22
PMD's Cash-to-Debt is ranked lower than
63% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.04 vs. PMD: 2.22 )
Ranked among companies with meaningful Cash-to-Debt only.
PMD' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.46  Med: No Debt Max: No Debt
Current: 2.22
Equity-to-Asset 0.64
PMD's Equity-to-Asset is ranked higher than
56% of the 201 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. PMD: 0.64 )
Ranked among companies with meaningful Equity-to-Asset only.
PMD' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.4  Med: 0.8 Max: 0.93
Current: 0.64
0.4
0.93
Interest Coverage 136.04
PMD's Interest Coverage is ranked higher than
52% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 80.49 vs. PMD: 136.04 )
Ranked among companies with meaningful Interest Coverage only.
PMD' s Interest Coverage Range Over the Past 10 Years
Min: 136.04  Med: No Debt Max: No Debt
Current: 136.04
Piotroski F-Score: 8
Altman Z-Score: 9.86
Beneish M-Score: -2.43
WACC vs ROIC
7.78%
56.67%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 29.11
PMD's Operating Margin % is ranked higher than
93% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.12 vs. PMD: 29.11 )
Ranked among companies with meaningful Operating Margin % only.
PMD' s Operating Margin % Range Over the Past 10 Years
Min: 5.45  Med: 20.88 Max: 29.11
Current: 29.11
5.45
29.11
Net Margin % 19.29
PMD's Net Margin % is ranked higher than
92% of the 203 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.10 vs. PMD: 19.29 )
Ranked among companies with meaningful Net Margin % only.
PMD' s Net Margin % Range Over the Past 10 Years
Min: 5.6  Med: 12.97 Max: 19.29
Current: 19.29
5.6
19.29
ROE % 59.58
PMD's ROE % is ranked higher than
97% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.64 vs. PMD: 59.58 )
Ranked among companies with meaningful ROE % only.
PMD' s ROE % Range Over the Past 10 Years
Min: 12.33  Med: 27.12 Max: 59.58
Current: 59.58
12.33
59.58
ROA % 33.46
PMD's ROA % is ranked higher than
97% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.30 vs. PMD: 33.46 )
Ranked among companies with meaningful ROA % only.
PMD' s ROA % Range Over the Past 10 Years
Min: 6.51  Med: 22.36 Max: 33.46
Current: 33.46
6.51
33.46
ROC (Joel Greenblatt) % 74.31
PMD's ROC (Joel Greenblatt) % is ranked higher than
85% of the 220 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.22 vs. PMD: 74.31 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
PMD' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 8.54  Med: 72.02 Max: 202.99
Current: 74.31
8.54
202.99
3-Year Revenue Growth Rate 12.10
PMD's 3-Year Revenue Growth Rate is ranked higher than
72% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. PMD: 12.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
PMD' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -10  Med: 10.15 Max: 134.5
Current: 12.1
-10
134.5
3-Year EBITDA Growth Rate 22.30
PMD's 3-Year EBITDA Growth Rate is ranked higher than
77% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.50 vs. PMD: 22.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
PMD' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -31.3  Med: 7.1 Max: 47.1
Current: 22.3
-31.3
47.1
3-Year EPS without NRI Growth Rate 19.20
PMD's 3-Year EPS without NRI Growth Rate is ranked higher than
72% of the 124 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.70 vs. PMD: 19.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
PMD' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -55  Med: 0 Max: 138.1
Current: 19.2
-55
138.1
GuruFocus has detected 3 Warning Signs with Psychemedics Corp $PMD.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» PMD's 10-Y Financials

Financials (Next Earnings Date: 2017-07-26 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

PMD Guru Trades in Q1 2016

Chuck Royce 37,500 sh (unchged)
Jim Simons 410,400 sh (-5.85%)
» More
Q2 2016

PMD Guru Trades in Q2 2016

Chuck Royce 37,500 sh (unchged)
Jim Simons 407,100 sh (-0.80%)
» More
Q3 2016

PMD Guru Trades in Q3 2016

Jim Simons 434,700 sh (+6.78%)
Chuck Royce 37,500 sh (unchged)
» More
Q4 2016

PMD Guru Trades in Q4 2016

Jim Simons 499,990 sh (+15.02%)
Chuck Royce 37,500 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with PMD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 621511    SIC: 8071
Compare:NAS:AIQ, NAS:CTSO, AMEX:VNRX, NAS:VRML, NAS:CGIX, NAS:TRIB, OTCPK:EDTXF, NAS:CEMI, NAS:TTOO, NAS:FLDM, NAS:HTGM, AMEX:SENS, NAS:BIOC, AMEX:PTN, OTCPK:PRFMF, OTCPK:SYGWF, NAS:TROV, OTCBB:INIS, NAS:CAPN, NAS:CHEK » details
Headquarter Location:USA
Psychemedics Corp provides testing services for the detection of drugs of abuse through the analysis of hair samples. This information is useful to employers for both applicant and employee testing, as well as to physicians and among others.

Psychemedics Corp is a Delaware corporation organized on September 24, 1986. The Company is a provider of hair testing for drugs of abuse, utilizing a patented hair analysis method involving digestion of hair, enzyme immunoassay technology and confirmation by mass spectrometry to analyze human hair to detect abused substances. The Company's tests provide quantitative information that can indicate the approximate amount of drug ingested as well as historical data, which can show a pattern of individual drug use over a longer period of time, thereby providing superior detection compared to other types of drug testing. This information is useful to employers for both applicant and employee testing, as well as to physicians, treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use. The Company markets its corporate drug testing services through its own sales force and through distributors. Sales offices are located in cities in the United States in order to facilitate communications with corporate employers. The Company markets its home drug testing service, PDT-90, through the Internet. The Company's customers include Fortune 500 companies, as well as small to mid-size corporations, schools and governmental entities located in the United States and internationally. The Company competes directly with commercial laboratories that test for drugs mainly through urinalysis testing. The Company is licensed as a clinical laboratory by the State of California as well as certain other states.

Top Ranked Articles about Psychemedics Corp

DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Psychemedics Corporation (PMD) & Lead Plaintiff Deadline - April 3, 2017

NEW YORK, March 30, 2017 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Psychemedics Corporation (“Psychemedics” or the “Company”) (NASDAQ:PMD) and certain of its officers, on behalf of a class who purchased Psychemedics securities between February 28, 2014 and January 30, 2017, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/pmd.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.
The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) through its affiliate Psychemedics Brasil Exames Toxicológicos Ltda., Psychemedics engaged in anticompetitive conduct to maintain a monopoly over the Brazilian market in violation of the law; (2) effectively, Psychemedics lacked effective internal controls over financial reporting; and (3) consequently, Psychemedics’ public statements were materially false and misleading at all relevant times.
On January 31, 2017, it was revealed that Psychemedics Brasil Exames Toxicológicos Ltda., Psychemedics’ local representative in Brazil, was ordered to compensate Omega Laboratories, Inc. USA for losses caused by anticompetitive practices used for “preventing other companies from accessing (the) market,” on January 20, 2017. Following this news, Psychemedics stock dropped during intra-day trading on January 31, 2017. A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/pmd or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Psychemedics you have until April 3, 2017 to request that the Court appoint you as lead plaintiff.  Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration.   Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]

Read more...
DEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those With Losses In Excess Of $100,000 From Investment In Psychemedics Corporation To Contact The Firm

STEVENSON, Md., March 29, 2017 (GLOBE NEWSWIRE) -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of purchasers of Psychemedics Corporation (NASDAQ:PMD) (“Psychemedics” or the “Company”) common stock during the period between February 28, 2014 and January 31, 2017, inclusive (the “Class Period”).  Investors who wish to become proactively involved in the litigation have until April 3, 2017 to seek appointment as lead plaintiff.
If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff and be selected by the Court.  The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the Class in the action.  The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Psychemedics common stock during the Class Period.  Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff.  No class has yet been certified in the above action. The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that Psychemedics’ Brazilian distributor, Psychemedics Brazil, was engaged in illegal anti-competitive practices and may be subject to further investigation by Brazil’s Administrative Council for Economic Defense as a result of the conduct. According to the complaint, following a January 31, 2017 press release announcing that a Brazilian court had found Psychemedics Brazil in violation of anti-competition laws and liable for millions in losses, the value of Psychemedics shares declined significantly. If you have suffered a loss in excess of $100,000 from investment in Psychemedics common stock purchased on or after February 28, 2014 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentsecuritiescases.html.  You may also request more information by contacting Brower Piven either by email at [email protected] or by telephone at (410) 415-6616.  Brower Piven also encourages anyone with information regarding the Company’s conduct during the period in question to contact the firm, including whistleblowers, former employees, shareholders and others. Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s.  If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice.  You need take no action at this time to be a member of the class.
CONTACT:  Charles J. Piven
Brower Piven, A Professional Corporation
1925 Old Valley Road
Stevenson, Maryland 21153
Telephone: 410-415-6616
[email protected]

Read more...
PMD SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Psychemedics Corporation and a Lead Plaintiff Deadline of April 3, 2017

NEW YORK, March 28, 2017 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Massachusetts on behalf of investors who purchased Psychemedics Corporation (NASDAQ:PMD) securities between February 28, 2014 and January 30, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra/psychemedics-corporation. There is no cost or obligation to you. According to the complaint, throughout the Class Period, Psychemedics issued materially false and/or misleading statements and/or failed to disclose that Psychemedics’ Brazilian distributor, Psychemedics Brazil, was engaged in illegal anti-competitive practices and may be subject to further investigation by Brazil’s Administrative Council for Economic Defense as a result of this conduct. On January 31, 2017, Psychemedics issued a press release announcing that a Brazilian court had found Psychemedics Brazil in violation of anti-competition laws and is liable for millions in losses. If you suffered a loss in Psychemedics you have until April 3, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/psychemedics-corporation. Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]

Read more...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Filed in U.S. District Court to Recover Losses Suffered by Investors in Psychemedics Corporation

Sets Lead Plaintiff Deadline of April 3, 2017 -- PMD

NEW YORK, March 17, 2017 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired shares of Psychemedics Corporation (“Psychemedics”) (NASDAQ:PMD) between February 28, 2014 and January 30, 2017. You are hereby notified that Levi & Korsinsky has commenced the class action Daly v. Psychemedics Corporation, et al. (Case No. 1:17-cv-10186) in the USDC for the District of Massachusetts. Click here to view the complaint. To get more information go to: http://www.zlk.com/pslra/psychemedics-corporation or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you. The complaint alleges that, among other allegations, throughout the Class Period Psychemedics issued materially false and/or misleading statements and/or failed to disclose that Psychemedics’ Brazilian distributor, Psychemedics Brazil, was engaged in illegal anti-competitive practices and may be subject to further investigation by Brazil’s Administrative Council for Economic Defense as a result of this conduct. On January 31, 2017, Psychemedics issued a press release announcing that a Brazilian court had found Psychemedics Brazil in violation of anti-competition laws and is liable for millions in losses. Take Action: if you suffered a loss in Psychemedics you have until April 3, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:   
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street - 24th Floor
New York, NY 10004           
Tel: (212) 363-7500
Toll Free:  (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

Read more...
SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Psychemedics Corporation of Class Action Lawsuit and Upcoming Deadline – PMD

NEW YORK, March 17, 2017 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Psychemedics Corporation (“Psychemedics” or the “Company”) (NASDAQ:PMD) and certain of its officers.   The class action, filed in United States District Court, District of Massachusetts, is on behalf of a class consisting of investors who purchased or otherwise acquired Psychemedics securities, seeking to recover compensable damages caused by defendants’ violations of the Securities Exchange Act of 1934.
If you are a shareholder who purchased Psychemedics securities between February 28, 2014 and January 30, 2017, both dates inclusive, you have until April 3, 2017 to ask the Court to appoint you as Lead Plaintiff for the class.  A copy of the Complaint can be obtained at www.pomerantzlaw.com.   To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll free, ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and number of shares purchased.  [Click here to join this class action] Psychemedics Corporation provides patented, FDA-cleared services for the detection of drug abuse through the analysis of hair samples. The Company’s tests provide quantitative information that can indicate the approximate amount of drug ingested, as well as historical data, which can show a pattern of individual drug use over a longer period of time. The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects.  Specifically, Defendants made false and/or misleading statements and/or failed to disclose that:  (i) through its affiliate Psychemedics Brasil Exames Toxicológicos Ltda. (“Psychemedics Brasil”), the Company engaged in anticompetitive conduct to maintain a monopoly over the Brazilian market in violation of the law; (ii) in turn, Psychemedics lacked effective internal controls over financial reporting; and (iii) as a result of the foregoing, Psychemedics’ public statements were materially false and misleading at all relevant times. On January 31, 2017, Bloomberg reported that a Brazilian judge had ordered Psychemedics’ local representative in Brazil, Psychemedics Brasil, to compensate Omega Laboratories, Inc. USA for losses caused by anticompetitive practices used for the purpose of “preventing other companies from accessing (the) market,” an indemnification that may cost the Company millions of dollars.  The Bloomberg article further reported that Psychemedics Brasil may be further investigated by Brazil’s Administrative Council for Economic Defense for engaging in “cartel practices” in an attempt to form a drug testing monopoly. Psychemedics issued a press release in response to the Brazilian court order denying involvement in the lawsuit, stating that “Psychemedics Brasil has been a distributor of Psychemedics Corporation’s hair testing services for more than fifteen years” and that it expects their business in Brazil to “continue as usual.” On this news, Psychemedics’ share price fell $6.75, or 26.35%, to close at $18.87 on January 31, 2017. The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com
CONTACT:
Robert S. Willoughby
Pomerantz LLP
[email protected]

Read more...
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Psychemedics Corporation To Contact The Firm Before Lead Plaintiff Deadline

NEW YORK, March 15, 2017 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Psychemedics Corporation (“Psychemedics” or the “Company”) (NASDAQ:PMD) of the April 3, 2017 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company and certain officers. The lawsuit has been filed in the U.S. District Court for the District of Massachusetts on behalf of all those who purchased Psychemedics securities between February 28, 2014 and January 30, 2017 (the “Class Period”).  The case, Baughman v. Psychemedics Corporation et al, No. 1:17-cv-10191 was filed on February 3, 2017, and has been assigned to Judge Richard Gaylore Stearns. The lawsuit focuses on whether the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (i) through its affiliate, Psychemedics Brasil Exames Toxicológicos Ltda. (“Psychemedics Brasil”), the Company engaged in anticompetitive conduct to maintain a monopoly over the Brazilian market in violation of the law; (ii) subsequently, Psychemedics lacked effective internal controls over financial reporting; and (iii) as a result, the Company’s public statements were materially false and misleading. Specifically, on January 31, 2017, Bloomberg reported, among other things, that a Brazilian judge had ordered the Company’s local representative in Brazil, Psychemedics Brasil, to compensate Omega Laboratories, Inc. USA for losses caused by anticompetitive practices used for the purpose of “preventing other companies from accessing (the) market,” an indemnification that may cost the Company millions of dollars. On this news, Psychemedics’ share price fell from $25.62 per share on January 30, 2017 to a closing price of $18.87 on January 31, 2017 — a $6.75 or a 26.35% drop. Request more information now by clicking here: www.faruqilaw.com/PMD. There is no cost or obligation to you. Take Action If you invested in Psychemedics securities between February 28, 2014 and January 30, 2017 and would like to discuss your legal rights, visit www.faruqilaw.com/PMD. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to [email protected].  Faruqi & Faruqi, LLP also encourages anyone with information regarding Psychemedics’ conduct to contact the firm, including whistleblowers, former employees, shareholders and others. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class that is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff. 

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

FARUQI & FARUQI, LLP
685 Third Avenue, 26th Floor
New York, NY 10017
Attn:  Richard Gonnello, Esq.
[email protected]
Telephone: (877) 247-4292 or (212) 983-9330

Read more...
ALERT: Rosen Law Firm Reminds Psychemedics Corporation Investors of Important Deadline in Class Action – PMD

NEW YORK, March 13, 2017 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Psychemedics Corporation securities (NASDAQ:PMD) from February 28, 2014 through January 30, 2017, inclusive (the “Class Period”) of the important April 3, 2017 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Psychemedics investors under the federal securities laws. To join the Psychemedics class action, go to http://rosenlegal.com/cases-1047.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action. NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. According to the lawsuit, throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) through its affiliate Psychemedics Brasil Exames Toxicologicos Ltda., Psychemedics engaged in anticompetitive conduct to maintain a monopoly over the Brazilian market in violation of the law; (2) in turn, Psychemedics lacked effective internal controls over financial reporting; and (3) as a result, Psychemedics’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 3, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-1047.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected]. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm. Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.  Attorney Advertising.  Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
Kevin Chan, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY  10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com

Read more...

Ratios

vs
industry
vs
history
PE Ratio 12.91
PMD's PE Ratio is ranked higher than
84% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.62 vs. PMD: 12.91 )
Ranked among companies with meaningful PE Ratio only.
PMD' s PE Ratio Range Over the Past 10 Years
Min: 9.07  Med: 20.15 Max: 64.78
Current: 12.91
9.07
64.78
PE Ratio without NRI 12.91
PMD's PE Ratio without NRI is ranked higher than
84% of the 104 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.50 vs. PMD: 12.91 )
Ranked among companies with meaningful PE Ratio without NRI only.
PMD' s PE Ratio without NRI Range Over the Past 10 Years
Min: 9.07  Med: 20.15 Max: 64.78
Current: 12.91
9.07
64.78
Price-to-Owner-Earnings 19.25
PMD's Price-to-Owner-Earnings is ranked higher than
72% of the 64 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 26.82 vs. PMD: 19.25 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
PMD' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 7.5  Med: 22.43 Max: 185.89
Current: 19.25
7.5
185.89
PB Ratio 6.38
PMD's PB Ratio is ranked lower than
77% of the 196 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.69 vs. PMD: 6.38 )
Ranked among companies with meaningful PB Ratio only.
PMD' s PB Ratio Range Over the Past 10 Years
Min: 1.98  Med: 5.78 Max: 9.8
Current: 6.38
1.98
9.8
PS Ratio 2.70
PMD's PS Ratio is ranked higher than
58% of the 195 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.36 vs. PMD: 2.70 )
Ranked among companies with meaningful PS Ratio only.
PMD' s PS Ratio Range Over the Past 10 Years
Min: 0.92  Med: 2.59 Max: 4.48
Current: 2.7
0.92
4.48
Price-to-Free-Cash-Flow 14.71
PMD's Price-to-Free-Cash-Flow is ranked higher than
76% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.50 vs. PMD: 14.71 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
PMD' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 6.67  Med: 19.65 Max: 86.36
Current: 14.71
6.67
86.36
Price-to-Operating-Cash-Flow 11.39
PMD's Price-to-Operating-Cash-Flow is ranked higher than
74% of the 86 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.60 vs. PMD: 11.39 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
PMD' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.95  Med: 15.81 Max: 26.06
Current: 11.39
5.95
26.06
EV-to-EBIT 8.69
PMD's EV-to-EBIT is ranked higher than
91% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.08 vs. PMD: 8.69 )
Ranked among companies with meaningful EV-to-EBIT only.
PMD' s EV-to-EBIT Range Over the Past 10 Years
Min: 4.1  Med: 11.9 Max: 81.9
Current: 8.69
4.1
81.9
EV-to-EBITDA 7.60
PMD's EV-to-EBITDA is ranked higher than
86% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.34 vs. PMD: 7.60 )
Ranked among companies with meaningful EV-to-EBITDA only.
PMD' s EV-to-EBITDA Range Over the Past 10 Years
Min: 3.7  Med: 10.9 Max: 28.4
Current: 7.6
3.7
28.4
PEG Ratio 3.90
PMD's PEG Ratio is ranked lower than
65% of the 43 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.96 vs. PMD: 3.90 )
Ranked among companies with meaningful PEG Ratio only.
PMD' s PEG Ratio Range Over the Past 10 Years
Min: 0.47  Med: 1.24 Max: 137.61
Current: 3.9
0.47
137.61
Shiller PE Ratio 28.45
PMD's Shiller PE Ratio is ranked higher than
67% of the 30 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 39.15 vs. PMD: 28.45 )
Ranked among companies with meaningful Shiller PE Ratio only.
PMD' s Shiller PE Ratio Range Over the Past 10 Years
Min: 6.64  Med: 18.62 Max: 38.91
Current: 28.45
6.64
38.91
Current Ratio 2.41
PMD's Current Ratio is ranked lower than
51% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. PMD: 2.41 )
Ranked among companies with meaningful Current Ratio only.
PMD' s Current Ratio Range Over the Past 10 Years
Min: 0.67  Med: 4.6 Max: 14
Current: 2.41
0.67
14
Quick Ratio 2.41
PMD's Quick Ratio is ranked higher than
56% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.15 vs. PMD: 2.41 )
Ranked among companies with meaningful Quick Ratio only.
PMD' s Quick Ratio Range Over the Past 10 Years
Min: 0.56  Med: 4.55 Max: 14
Current: 2.41
0.56
14
Days Sales Outstanding 32.51
PMD's Days Sales Outstanding is ranked higher than
63% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 62.33 vs. PMD: 32.51 )
Ranked among companies with meaningful Days Sales Outstanding only.
PMD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 32.51  Med: 57.01 Max: 70.9
Current: 32.51
32.51
70.9
Days Payable 12.28
PMD's Days Payable is ranked lower than
76% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 53.45 vs. PMD: 12.28 )
Ranked among companies with meaningful Days Payable only.
PMD' s Days Payable Range Over the Past 10 Years
Min: 8.99  Med: 22.11 Max: 36.51
Current: 12.28
8.99
36.51

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 3.13
PMD's Dividend Yield % is ranked higher than
81% of the 101 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.97 vs. PMD: 3.13 )
Ranked among companies with meaningful Dividend Yield % only.
PMD' s Dividend Yield % Range Over the Past 10 Years
Min: 2.27  Med: 4.59 Max: 18.28
Current: 3.13
2.27
18.28
Dividend Payout Ratio 0.49
PMD's Dividend Payout Ratio is ranked lower than
77% of the 60 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.24 vs. PMD: 0.49 )
Ranked among companies with meaningful Dividend Payout Ratio only.
PMD' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.49  Med: 0.98 Max: 2.14
Current: 0.49
0.49
2.14
Forward Dividend Yield % 3.08
PMD's Forward Dividend Yield % is ranked higher than
77% of the 91 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.15 vs. PMD: 3.08 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 3.62
PMD's 5-Year Yield-on-Cost % is ranked higher than
78% of the 106 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.33 vs. PMD: 3.62 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
PMD' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.66  Med: 5.37 Max: 21.4
Current: 3.62
2.66
21.4
3-Year Average Share Buyback Ratio -0.90
PMD's 3-Year Average Share Buyback Ratio is ranked higher than
73% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.00 vs. PMD: -0.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PMD' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -32.8  Med: -0.5 Max: 1.9
Current: -0.9
-32.8
1.9

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 40.66
PMD's Price-to-Net-Current-Asset-Value is ranked lower than
96% of the 122 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.79 vs. PMD: 40.66 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
PMD' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 3.53  Med: 11.02 Max: 94.92
Current: 40.66
3.53
94.92
Price-to-Tangible-Book 6.35
PMD's Price-to-Tangible-Book is ranked lower than
61% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.28 vs. PMD: 6.35 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
PMD' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.97  Med: 8.05 Max: 17.34
Current: 6.35
2.97
17.34
Price-to-Intrinsic-Value-Projected-FCF 2.86
PMD's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
61% of the 70 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.10 vs. PMD: 2.86 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
PMD' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.69  Med: 2.56 Max: 21.65
Current: 2.86
0.69
21.65
Price-to-Median-PS-Value 1.04
PMD's Price-to-Median-PS-Value is ranked lower than
54% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. PMD: 1.04 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
PMD' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.57  Med: 1.67 Max: 14.83
Current: 1.04
0.57
14.83
Price-to-Graham-Number 1.90
PMD's Price-to-Graham-Number is ranked higher than
67% of the 61 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.97 vs. PMD: 1.90 )
Ranked among companies with meaningful Price-to-Graham-Number only.
PMD' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.27  Med: 3.07 Max: 15.19
Current: 1.9
1.27
15.19
Earnings Yield (Greenblatt) % 11.50
PMD's Earnings Yield (Greenblatt) % is ranked higher than
94% of the 297 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.45 vs. PMD: 11.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
PMD' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.2  Med: 8.4 Max: 24.3
Current: 11.5
1.2
24.3
Forward Rate of Return (Yacktman) % 0.23
PMD's Forward Rate of Return (Yacktman) % is ranked lower than
73% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.75 vs. PMD: 0.23 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
PMD' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -9.6  Med: 6.9 Max: 40.8
Current: 0.23
-9.6
40.8

More Statistics

Revenue (TTM) (Mil) $42.52
EPS (TTM) $ 1.49
Beta0.96
Short Percentage of Float0.79%
52-Week Range $10.81 - 27.46
Shares Outstanding (Mil)5.46
» More Articles for PMD

Headlines

Articles On GuruFocus.com
Psychemedics Corporation Announces Record Q1 Revenues And Earnings Apr 25 2017 
DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Psychem Mar 30 2017 
DEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadline In Class Action Lawsuit And Mar 29 2017 
PMD SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Mar 28 2017 
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Filed in U.S. District Court to Mar 17 2017 
SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ps Mar 17 2017 
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,0 Mar 15 2017 
ALERT: Rosen Law Firm Reminds Psychemedics Corporation Investors of Important Deadline in Class Acti Mar 13 2017 
Psychemedics Remains Undervalued Even After Run-up Aug 22 2016 
Psychemedics Corp. on Cusp of Significant Revenue Growth Apr 17 2016 

More From Other Websites
Psychemedics posts 1Q profit Apr 25 2017
Psychemedics Corporation Announces Record Q1 Revenues And Earnings Apr 25 2017
DEADLINE TODAY: Khang & Khang LLP Announces Securities Class Action Lawsuit against Psychemedics... Apr 03 2017
FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against... Apr 03 2017
MONDAY DEADLINE ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Psychemedics... Mar 31 2017
UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Shareholders It Has Filed in U.S. District Court to... Mar 31 2017
April 3 Deadline Alert: Law Offices of Howard G. Smith Reminds Psychemedics Corporation Investors of... Mar 31 2017
DEADLINE MONDAY: Khang & Khang LLP Announces Securities Class Action Lawsuit against Psychemedics... Mar 30 2017
DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against... Mar 30 2017
APRIL 3 DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit Against Psychemedics... Mar 29 2017
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds Investors in Psychemedics Corporation of Imminent... Mar 29 2017
DEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadline In Class Action Lawsuit And... Mar 29 2017
IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit Against... Mar 28 2017
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against... Mar 28 2017
PMD SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving... Mar 28 2017
SHAREHOLDER ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit Against Psychemedics... Mar 27 2017
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds Investors In Psychemedics Corporation Of Imminent... Mar 26 2017
INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Psychemedics... Mar 24 2017
DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against... Mar 24 2017
Psychemedics Corp. :PMD-US: Earnings Analysis: Q4, 2016 By the Numbers : March 22, 2017 Mar 22 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)